Document is current

Article History

Received: 30 September 2024

Accepted: 3 February 2025

First Online: 19 February 2025

Declarations

:

: All participants provided informed consent, and the study protocols were approved by the appropriate ethical review boards. TRIAD was approved by the Montreal Neurological Institute PET working committee and the Douglas Mental Health University Institute Research Ethics Board (IUSMD16-61, IUSMD16-60).

: Not applicable.

: NJA has given lectures, produced educational materials, and participated in educational programs for Eli-Lily, BioArtic, Quanterix. E.R.Z serves on the scientific advisory board of Next Innovative Therapeutics and is cofounder and member of the scientific advisory board of Masima. KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, Sanofi and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).